Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.33 |
| ▸ | PDE6A | P16499 | 1/20 | 0.33 |
| ▸ | PDE6G | P18545 | 1/20 | 0.33 |
| ▸ | PDE6B | P35913 | 1/20 | 0.33 |
| ▸ | PDE6C | P51160 | 1/20 | 0.33 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 8/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830402 | 0.84 | ACACB (0.45) | ACACBCDK1CDK2PDE6DPDE6A | |
| SCHEMBL22131921 | 0.80 | ACACB (0.49) | ACACBCDK1CDK2FFAR2CNR2 | |
| SCHEMBL20775322 | 0.77 | ACACB (0.44) | ACACBCDK1CDK2HRH3FFAR2 | |
| SCHEMBL23830298 | 0.70 | ACACB (0.47) | ACACBCNR2GPR119CNR1 | |
| SCHEMBL22247426 | 0.69 | CNR2 (0.39) | ACACBHRH3CNR2CNR1 | |
| SCHEMBL19004847 | 0.69 | CDK1 (0.39) | ACACBCDK1CDK2FFAR2 | |
| SCHEMBL20732647 | 0.65 | ACACB (0.39) | ACACBCDK1CDK2FFAR2 | |
| SCHEMBL16187539 | 0.65 | ACACB (0.39) | ACACBCDK1CDK2CNR2 | |
| SCHEMBL25206883 | 0.65 | CDK2 (0.41) | ACACBCDK1CDK2FFAR2CNR2 | |
| SCHEMBL22131966 | 0.64 | ACACB (0.55) | ACACBCDK1CDK2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | US | disclosed |
| CN-112543757-A | Condensed azaheteroaryl compounds having antibacterial activity against tubercle bacillus | 卡迪拉保健有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292333-A1 | CONDENSED AZAHETEROARYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY AGAINST TUBERCULOSIS BACTERIA | DPEP1, SAT1, PEPD | ACACB 1645/4885CDK1 563/4885CDK2 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.